Oral Cancer News

Vaccine law should cover HPV cancers

Source: www.sacbee.com Author: Brandon Brown Vaccines are the most effective way to prevent infectious diseases. Gov. Jerry Brown rightly signed a law that requires, starting July 1, 2016, that all children enrolled in public or private schools or day care be vaccinated against whooping cough, measles, polio and other diseases, regardless of parents’ religious or personal beliefs. But frustratingly, the California mandate does not include the vaccine to protect against cervical, anal and oral cancers, and genital warts. HPV vaccines have been around for 10 years. Three types exist, with the newest providing the highest protection against chronic infection and precancerous conditions among boys and girls. Despite the recommendations of major health groups, national data show only 57 percent of adolescent females and 35 percent of males received at least one dose of the three-dose HPV vaccine series in 2013. HPV vaccine has the lowest completion rate of any vaccine in the United States. There may be several explanations for this. One is the short time that providers have available to stress the need for early vaccination during a normal medical visit, much less to address parents’ concerns about implicitly sanctioning sexual activity. But the vaccine is linked to age rather than sexual activity, and postponing it until after boys and girls start having sex decreases its effectiveness. Another reason for low vaccination rates is that it requires tremendous work, including training health care providers on how to promote HPV vaccine as a cancer-prevention tool similar to hepatitis B vaccine, [...]

Oral Cancer Foundation News Team - A2015-09-23T07:26:41-07:00September, 2015|Oral Cancer News|

Spreading awareness and saving lives — Oral Cancer Foundation’s Walk for Awareness may be coming to a city near you!

Source: www.prnewswire.com Author: press release Oral cancer has historically existed outside the awareness of much of the public, yet in the U.S. it claims one life every hour of every day of the year. This year alone, approximately 45,750 Americans will be diagnosed with oral cancer. This number is on the rise and The Oral Cancer Foundation (OCF) needs help spreading awareness about this devastating disease. OCF is working in communities across the country to bring "Walk for Awareness" events to the public, and with them the opportunity to engage in a conversation that too few people are having. These events raise awareness of a disease that far too many Americans have never even heard of. Most events also incorporate free to the public oral cancer screenings, providing the opportunity to educate attendees about the early signs and symptoms of oral cancer while also instilling the importance of early detection and need for annual oral cancer screenings. To see if an OCF Walk for Awareness is taking place near you, visit oralcancer.org and click support to view an interactive map of the organization's upcoming events. OCF has been raising awareness and providing support in communities for 16 years in cities scattered across the US. Here are a just a few of the remaining Fall 2015 events: The 5th Annual Oral Cancer Foundation Walk/Fun Run for Awareness - Twin Cities, Minnesota, will take place this Sunday, September 27, 2015 at City of Eagan Community Center. For more details, to register and [...]

Oral Cancer Foundation News Team - A2015-10-13T20:24:31-07:00September, 2015|OCF In The News, Oral Cancer News|

Vaccine clears some precancerous cervical lesions in clinical trial

Source: www.sciencedaily.comAuthor: Mark L Bagarazzi, MD et al. Scientists have used a genetically engineered vaccine to successfully eradicate high-grade precancerous cervical lesions in nearly one-half of women who received the vaccine in a clinical trial. The goal, say the scientists, was to find nonsurgical ways to treat precancerous lesions caused by HPV. "Every standard therapeutic option for women with these lesions destroys part of the cervix, which is particularly relevant for women of childbearing age, who may then be at risk for preterm birth due to a weakened cervix," says Cornelia Trimble, M.D., professor of gynecology and obstetrics, oncology, and pathology at the Johns Hopkins University School of Medicine, and first author of the new report, which appears online Sept. 17 in The Lancet. "A vaccine able to cure precancerous lesions could eventually be one way women can avoid surgery that is invasive and can also harm their fertility." High-grade cervical lesions, termed CIN2/3, occur most often in women 40 or younger, according to Trimble, a member of Johns Hopkins' Kelly Gynecologic Oncology Service and Kimmel Cancer Center. Because the lesions can progress to cancer, they are usually removed by surgery, freezing or laser. The procedures are successful in removing the precancerous areas in approximately 80 percent of women, says Trimble. Less troublesome lesions, called low-grade dysplasia, are usually monitored by physicians rather than immediately removed because they pose less of a risk for cancer and usually regress on their own. For the study, the scientists used a vaccine, originally developed [...]

Charlotte Parker2015-09-21T17:41:30-07:00September, 2015|Oral Cancer News|

Imaging method has potential to stratify head and neck cancer patients

Source: www.eurekalert.org Author: press release Manchester researchers have identified a potential new way to predict which patients with head and neck cancer may benefit most from chemotherapy. These patients commonly receive pre-treatment induction chemotherapy, before either surgery or radiotherapy, to reduce the risk of disease spread. However the effectiveness of such treatment is reduced in tumours with poor blood flow. Previous studies have shown that CT scans can be used to assess tumour blood flow. Now researchers at The University of Manchester and The Christie NHS Foundation Trust - both part of the Manchester Cancer Research Centre - have explored the use of MRI scans in predicting which patients would benefit from induction chemotherapy. Professor Catharine West, who led the study, said: "It's also important to identify those patients who are unlikely to respond to induction therapy so that we can skip ahead in the treatment pathway and offer them potentially more effective treatments and hopefully improve their outcome." The team used an imaging technique known as dynamic contrast-enhanced MRI (DCE-MRI), where a contrast agent tracer is injected into a patient's vein whilst they have a series of MRI scans taken. This allows scientists and doctors to investigate the blood flow and vessel structure of a patient's tumour. They found that the blood flow of a patient's tumour before they received induction therapy could predict response to treatment. In a paper recently published in the journal Oral Oncology, the group report that those with high tumour blood flow were more [...]

Oral Cancer Foundation News Team - A2015-09-19T08:39:53-07:00September, 2015|Oral Cancer News|

FDA Grant Forwards Listeria-Based Throat Cancer Vaccine

Source: www.targetedonc.comAuthor: Sandra Kear An experimental immunotherapy for human papillomavirus-, or HPV-, related throat cancers, which is driven by the Listeria bacteria (that wreaks havoc when ingested), may now move forward due to a $1.1 million dollar grant from the FDA to researchers at Baylor College of Medicine. “Immunotherapy, such as axalimogene filolisbac, which targets HPV proteins expressed in cancer cells is a great example of using a cancer’s own unique biology against it.” said principal investigator Andrew Sikora, MD, PhD, leader of the head and neck cancer program in the NCI Comprehensive Designated Dan L. Duncan Cancer Center and an associate professor of otolaryngology at Baylor College, in an interview with Targeted Oncology. "This is hopefully the first step toward development of more targeted treatment approaches that reduce side effects and cancer treatment-related morbidity by uniquely targeting only virus-infected cells.”  The Listeria-based HPV immunotherapy, axalimogene filolisbac (ADXS11-001), is developed by Advaxis, and functions by stimulating an immune response against HPV proteins, thus killing infected cells. The drug is currently being evaluated in phase I-II study3 alone or in combination with MedImmune’s durvalumab, in patients with cervical or HPV-positive head and neck cancer. The study has three arms: axalimogene filolisbac alone, durvalumab alone, and the two drugs combined. Primary outcomes established for the study are: number of subjects with adverse events (AEs) in each dose level, number of subjects with AEs in the combination dose, and progression-free survival. Patients must have measurable disease by RECIST criteria, as well [...]

Charlotte Parker2015-09-17T09:22:55-07:00September, 2015|Oral Cancer News|

Smokeless tobacco use on the rise among high school athletes

Source: kimt.com Author: Jeron Rennie A new Centers for Disease Control and Prevention (CDC) report shows a trend they don’t want to see. A Morbidity and Mortality Weekly Report (MMWR) shows that from 2001-2013, smokeless tobacco use increased significantly among high school athletes, but not with non-athletes. The report also found there was lower use of combustible tobacco products among athletes than non-athletes. The CDC said that could be due, in part, to an awareness of the negative consequences on athletic performance. However, they say the use of smokeless tobacco suggests they find those products as being harmless. “When you see it in the media and you see all those athletes that you’re looking up to as a younger student and trying to reach some of the goals that they’ve reached,” said Freeborn County Drug-Free Coalition Prevention Coordinator Lana Howe. “It definitely plays a large impact on you as a youth.” The CDC said using smokeless tobacco can, however, adversely impact athletic performance and lead to disease and early death since they contain nicotine, toxins and carcinogens. Several athletes with a history of smokeless tobacco use have been diagnosed with, or died from, oral cancer.

Oral Cancer Foundation News Team - A2015-09-13T15:20:13-07:00September, 2015|Oral Cancer News|

UC Davis will use dogs to sniff out cancer

Source: www.willitsnews.com Author: staff A university team of physicians, veterinarians and animal behaviorists has begun training a pair of very special canines to sniff out cancer. One of the 4-month-old puppies is Alfie, a Labradoodle. months old. UC Davis clinicians are hoping to advance cancer screenings with the innate olfactory skills of man’s best friend. A university team of physicians, veterinarians and animal behaviorists has begun training a pair of very special canines who may represent high-tech health care on four feet in the effort to better screen for cancer, especially at early stages of the disease. About 4-months old, the puppies Alfie (a Labradoodle) and Charlie (a German Shepherd) are undergoing a rigorous twelve-month training program to develop their abilities to identify the scent of cancer in samples of saliva, breath and urine. According to sensory scientists, the olfactory acuity of dogs enables them to detect odorant concentration levels at 1 to 2 parts per trillion, roughly 10,000 to 100,000 times that of a human. UCD physicians and researchers believe Alfie and Charlie have the potential to add an important diagnostic element to patient care. Cancer is the second leading cause of death in the United States, and early detection of the disease gives patients the best chance of survival. “For the past number of years, we have been developing very high-end, expensive new tests to try and detect the presence of cancer,” said Ralph de Vere White, distinguished professor of urology and director of the UC [...]

Oral Cancer Foundation News Team - A2015-09-13T15:14:35-07:00September, 2015|Oral Cancer News|

Cowboy with a statement on smoking

Source: www.vp-mi.comAuthor: Adam Robertson A cowboy stands against smoking Above: Cody Kiser holds on as his bronco goes wild during the Sanders County Fair rodeo; Kiser has teamed up with the Oral Cancer Foundation to raise awareness of the dangers of tobacco products through the rodeo. PLAINS - Tobacco use has been a big part of the rodeo for years; one participant of the Sanders County Fair is in the forefront of changing this, though, by promoting a tobacco-less lifestyle through the sport. Cody Kiser, a cowboy who rode bareback broncos at the Fair, has teamed up with the Oral Cancer Foundation’s ‘Be Smart, Don’t Start’ campaign to help teach kids about the dangers of tobacco products and oral cancer. According to their website, the campaign is part of the foundation’s rodeo outreach and attempting to “become engaged where the problem lives.” “While other [groups] are focused on getting users to quit, the Oral Cancer Foundation is reaching out to young people to not pick up the habit that they may see one of their rodeo heroes engaging in,” stated information provided by the OFC. To help with this, Kiser and the foundation have been working to present role models within the rodeo world who do not use tobacco products and actively advocate against their use. “How do you change that?” Kiser asked, regarding the tobacco-use culture. “I think that is in kids; you have to get to the kids and get their opinions changed.” The foundation’s main focus [...]

Charlotte Parker2015-09-11T11:24:26-07:00September, 2015|OCF In The News, Oral Cancer News|

Raising awareness at the rodeo

Source: www.dailyrecordnews.comAuthor: Nicole Klauss A rodeo barrel racer from California is helping spread the word in Ellensburg that people shouldn’t start using tobacco. Carly Twisselman competed at the Ellensburg Rodeo slack Thursday night. She also helped share the message of the Oral Cancer Foundation, which is “Be smart. Don’t start.” While attending and competing at rodeo events, Twisselman reaches out to youth to encourage them not to pick up the habit they may see their rodeo heroes have. “The rodeo is known for having a lot of chewing tobacco. … The rodeo is such a small community and the heroes in it, the children look up to,” Twisselman said. “When they see their hero, growing up they think ‘I want to be like them.’” Campaign The Oral Cancer Foundation teamed up with Twisselman and bareback bronc rider Cody Kiser to spread the word in the rodeo circuit. The goal of the campaign is to spread awareness of oral cancer and the dangers of starting tobacco use. Twisselman often spends time talking to children and hands out buttons and bandannas to spread the message. Smokeless/spit tobacco is one of the historic causes of deadly oral cancers, and is more addictive than other forms of tobacco use, according to a news release from the Oral Cancer Foundation. According to the Oral Cancer Foundation’s website (www.oralcancer ocw.upc.edu.org), mouth cancers are newly diagnosed in about 115 people each day in the U.S., and worldwide new mouth cancer cases exceed 450,000 annually. When found at [...]

Charlotte Parker2015-09-08T12:54:02-07:00September, 2015|OCF In The News, Oral Cancer News|

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression

Source: www.nature.comAuthor: A E Rice, Y E Latchman, J P Balint, J H Lee, E S Gabitzsch and F R Jones We have investigated if immunotherapy against human papilloma virus (HPV) using a viral gene delivery platform to immunize against HPV 16 genes E6 and E7 (Ad5 [E1-, E2b-]-E6/E7) combined with programmed death-ligand 1 (PD-1) blockade could increase therapeutic effect as compared to the vaccine alone. Ad5 [E1-, E2b-]-E6/E7 as a single agent induced HPV-E6/E7 cell-mediated immunity. Immunotherapy using Ad5 [E1-, E2b-]-E6/E7 resulted in clearance of small tumors and an overall survival benefit in mice with larger established tumors. When immunotherapy was combined with immune checkpoint blockade, an increased level of anti-tumor activity against large tumors was observed. Analysis of the tumor microenvironment in Ad5 [E1-, E2b-]-E6/E7 treated mice revealed elevated CD8+ tumor infiltrating lymphocytes (TILs); however, we observed induction of suppressive mechanisms such as programmed death-ligand 1 (PD-L1) expression on tumor cells and an increase in PD-1+ TILs. When Ad5 [E1-, E2b-]-E6/E7 immunotherapy was combined with anti-PD-1 antibody, we observed CD8+ TILs at the same level but a reduction in tumor PD-L1 expression on tumor cells and reduced PD-1+ TILs providing a mechanism by which combination therapy favors a tumor clearance state and a rationale for pairing antigen-specific vaccines with checkpoint inhibitors in future clinical trials. *This news story was resourced by the Oral Cancer Foundation, and vetted for appropriateness and accuracy.

Charlotte Parker2015-09-08T09:28:07-07:00September, 2015|Oral Cancer News|